TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2’s involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45hiLy6C+ myeloid cells, but not on P2RY12+ parenchymal microglia. In AD mice deficient for TREM2, the CD45hiLy6C+ macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for TREM2+ macrophages in AD pathogenesis and an unexpected, detrimental role of TREM2 in AD pathology. These findings have direct implications for future development of TREM2-targeted therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trem2, a myeloid protein involved in microglial survival and proliferation, regulates a checkpoint necessary for DAM and deletion of Trem2 prevents microglial accumulation around Aβ plaques and leads to additional neuritic damage [6, 14–17].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [14]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“TREM2 was recently demonstrated to be essential for promoting microglial cell association with plaques44–49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Although numerous studies have reported that TREM2 expression is upregulated in amyloid plaque-associated microglia in vivo (Frank et al., 2008; Jay et al., 2015), our research is the first to show that PU.1 knockdown abrogates this phenomenon in vitro.”
From PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease (2025) · cites this paper as Jay et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [59]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [16]
Experimental — accuracy not yet measured
34 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“5XFAD mice (The Jackson Laboratory B6SJL-Tg(APPSwFlLon,PSEN1*M146*l286V)) express mutant human APP(695) with Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations and human PSEN1 with M146L and L286V mutations under control of the Thy1 promoter (Oakley et al., 2006).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Notably, variants of the immune cell– specific triggering receptor expressed on myeloid cells 2 (TREM2) confer dramatically elevated risk for developing AD (R. Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 3×
“First, we found that TREM2+ cells in AD mouse models 2013; Butovsky et al., 2014), was expressed by parenchymal, nonplaque-associated cells in APPPS1;Trem2+/+ mice (Fig.”
BackgroundSelf-citationIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“TREM2, along with its obligate intracellular adaptor DAP12, was identified as a hub gene in systems biology analyses in AD (Forabosco et al., 2013; Zhang et al., 2013), highlighting the central importance of these myeloid cell signaling elements CORRESPONDENCE Bruce T.”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“However, recent genome-wide association studies linked polymorphisms in inflammation-related genes to increased AD risk, supporting the conclusion that inflammation can be a causative factor in disease pathology (Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“The potential role of peripherally derived macrophages in AD has been controversial (Prinz and Priller, 2014), but it is well accepted that CD45hiLy6C+CCR2+ monocytes enter the central nervous system (CNS) and modulate pathology in other disease contexts (Mildner et al.”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Cited by
Items 101–200 of 683
Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system
Yang, S., Qin, C., Hu, Z.-W., Zhou, L.-Q., Yu, H.-H., Chen, M., Bosco, D. B., Wang, W., Wu, L.-J., & Tian, D.-S. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105290 · Cited by 232
Insulin Resistance in Alzheimer's Disease
Ferreira, L. S. S., Fernandes, C. S., Vieira, M. N. N., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00830 · Cited by 228
“Importantly, TREM2 polymorphisms also determines high risk for late-onset AD, but their role in neurodegenerative diseases are controversial (Jay et al., 2015; Wang et al., 2015).”
BackgroundThe roles of inflammation and immune mechanisms in Alzheimer's disease
Van Eldik, L. J., Carrillo, M. C., Cole, P. E., Feuerbach, D., Greenberg, B. D., Hendrix, J. A., Kennedy, M., Kozauer, N., Margolin, R. A., Molinuevo, J. L., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.05.001 · Cited by 225
Self-citationJurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
“It is still controversial whether TREM2 is important for resident microglia or in promoting infiltration of peripheral myeloid cells [180].”
BackgroundKober, D. L., Alexander-Brett, J. M., Karch, C. M., Cruchaga, C., Colonna, M., Holtzman, M. J., & Brett, T. J. (2016) · eLife · doi:10.7554/elife.20391 · Cited by 238
“DOI: 10.7554/eLife.20391.001”
InfluentialZhong, L., Wang, Z., Wang, D., Wang, Z., Martens, Y. A., Wu, L., Xu, Y., Wang, K., Li, J., Huang, R., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0247-7 · Cited by 217
“TREM2 deficiency was found to reduce the number of microglia clustering around Aβ plaques [21, 25, 26], sug-”
BackgroundResultThe role of the immune system in Alzheimer disease: Etiology and treatment
Jevtic, S., Sengar, A. S., Salter, M. W., & McLaurin, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.005 · Cited by 215
Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan
Tay, T. L., Béchade, C., D’Andrea, I., St-Pierre, M.-K., Henry, M. S., Roumier, A., & Tremblay, M.-E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00421 · Cited by 216
“Deletion or dominant negative mutations of Trem2 were shown to worsen AD progression in the 5xFAD and APP/PS1 mouse models of AD (Jay et al., 2015, 2017; Yuan et al., 2016; Ulland et al., 2017), but Trem2 deletion also reduced amyloid β burden, increased neuronal loss, prevented microglial…”
BackgroundActivated microglia mitigate Aβ-associated tau seeding and spreading
Gratuze, M., Chen, Y., Parhizkar, S., Jain, N., Strickland, M. R., Serrano, J. R., Colonna, M., Ulrich, J. D., & Holtzman, D. M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210542 · Cited by 215
Microglia and Neuroinflammation: What Place for P2RY12?
Gómez Morillas, A., Besson, V. C., & Lerouet, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041636 · Cited by 214
Microglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Meilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210
“Trem2 deletion in amyloidosis models has also been reported to either increase or decrease phosphorylation of the endogenous tau protein (Jay et al., 2015; Wang et al., 2016).”
BackgroundMethodResultInfluentialInflammation context in Alzheimer’s disease, a relationship intricate to define
Novoa, C., Salazar, P., Cisternas, P., Gherardelli, C., Vera-Salazar, R., Zolezzi, J. M., & Inestrosa, N. C. (2022) · Biological Research · doi:10.1186/s40659-022-00404-3 · Cited by 206
Li, R.-Y., Qin, Q., Yang, H.-C., Wang, Y.-Y., Mi, Y.-X., Yin, Y.-S., Wang, M., Yu, C.-J., & Tang, Y. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00542-y · Cited by 204
“contributes to AD pathogenesis In addition to the CNS, TREM2 in the periphery also plays a vital role in the development and progression of AD [17, 123].”
BackgroundThornton, P., Sevalle, J., Deery, M. J., Fraser, G., Zhou, Y., Ståhl, S., Franssen, E. H., Dodd, R. B., Qamar, S., Gomez Perez‐Nievas, B., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707673 · Cited by 200
“While there is experimental support for TREM2 playing such a protective role during amyloid plaque deposition (Wang et al, 2015; Yuan et al, 2016), there are also conflicting accounts (Jay et al, 2015).”
BackgroundSevenich, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00697 · Cited by 198
“demonstrated that Trem2 deficiency resulted in reduced infiltration of inflammatory myeloid cells and thereby ameliorated AD pathology at early stages (77) and exacerbated it at later stage (98).”
BackgroundAlzheimer’s Disease, Oligomers, and Inflammation
Forloni, G., & Balducci, C. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170819 · Cited by 194
The role of innate immune genes in Alzheimer's disease
Griciuc, A., & Tanzi, R. E. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000911 · Cited by 192
“Previous studies reported TREM2 knock-out decreased [30,88] or did not impact [89] Ab plaque burden during early disease.”
BackgroundResultChen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 189
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer’s Disease
Czapski, G. A., & Strosznajder, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111677 · Cited by 191
Cheng, Y., Tian, D.-Y., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 190
“A cluster of AD risk gene mutations have been found to compromise the phagocytic function of Aβ by monocytes [68, 122].”
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
“TREM2 sustains microglial response to Aβ TREM2 is constitutively expressed in microglia, but its expression ramps up after initiation of amyloid plaques [145].”
BackgroundTREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606370 · Cited by 183
“Jay et al (2015) reported a detrimental role of TREM2 in AD by demonstrating that its knockout leads to a reduction in the amyloid plaque load, inflammation, astrogliosis, and tau phosphorylation.”
The Role of APOE and TREM2 in Alzheimer′s Disease—Current Understanding and Perspectives
Wolfe, C. M., Fitz, N. F., Nam, K. N., Lefterov, I., & Koldamova, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010081 · Cited by 187
“utilizing APPPS1-21 mice found no change in the amyloid pathology in the cortex and a significant decrease in the hippocampus in Trem2−/− mice at 4 months [169].”
Methodβ-amyloid, microglia, and the inflammasome in Alzheimer’s disease
Gold, M., & El Khoury, J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0518-0 · Cited by 187
“More recent reports showed that cells expressing monocyte markers are associated with plaques in two transgenic models of Aβ deposition [60] and that adoptively transferred monocytes home in to these plaques [61].”
BackgroundTargeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
“Studies have consistently found a striking reduction in the number of microglia surrounding Ab plaques in AD mouse models genetically lacking one or both copies of TREM2 (Jay et al., 2015; Ulrich et al., 2014; Wang et al., 2015).”
BackgroundInfluentialExploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
Dionisio-Santos, D. A., Olschowka, J. A., & O’Banion, M. K. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1453-0 · Cited by 184
“Indeed, TREM2 deletion has been associated with an increase in the proportion of homeostatic microglia and a reduction in amyloid β plaques at early stages of amyloidogenesis [83, 89, 92].”
BackgroundTREM2 in CNS homeostasis and neurodegenerative disease
Painter, M. M., Atagi, Y., Liu, C.-C., Rademakers, R., Xu, H., Fryer, J. D., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0040-9 · Cited by 169
“activation in brain lysates of four-month old mice [70].”
BackgroundLouveau, A., Da Mesquita, S., & Kipnis, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.08.027 · Cited by 177
“962 Neuron 91, September 7, 2016 of TREM2 in particular, more studies are needed in order to fully understand its consequences on mononuclear cell recruitment, neurovascular dysfunction, and brain pathology in AD (Jay et al., 2015; Tanzi, 2015; Wang et al., 2015).”
InfluentialXiang, X., Piers, T. M., Wefers, B., Zhu, K., Mallach, A., Brunner, B., Kleinberger, G., Song, W., Colonna, M., Herms, J., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0280-6 · Cited by 170
“plaques, proliferation, phagocytosis of dead cells and amyloid fibrils are all reduced [8, 12, 13].”
BackgroundNuclear Receptors License Phagocytosis by Trem2+Myeloid Cells in Mouse Models of Alzheimer's Disease
Savage, J. C., Jay, T., Goduni, E., Quigley, C., Mariani, M. M., Malm, T., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4586-14.2015 · Cited by 154
“Importantly, Jay et al. (2015) have shown a dramatic decrease in monocyte infiltration in TREM2 / AD model mice and an absence of plaque-associated cells, suggesting that TREM2 has previously unappreciated roles in peripheral monocytes and their subsequent actions within the brain.”
BackgroundInfluentialSelf-citationViral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model
Fol, R., Braudeau, J., Ludewig, S., Abel, T., Weyer, S. W., Roederer, J.-P., Brod, F., Audrain, M., Bemelmans, A.-P., Buchholz, C. J., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1498-9 · Cited by 168
Wes, P. D., Holtman, I. R., Boddeke, E. W. G. M., Möller, T., & Eggen, B. J. L. (2016) · Glia · doi:10.1002/glia.22866 · Cited by 167
“It has also been suggested that TREM2 is expressed by infiltrating monocytes under pathological conditions (Jay et al., 2015).”
BackgroundNrf2 Suppresses Oxidative Stress and Inflammation in App Knock-In Alzheimer’s Disease Model Mice
Uruno, A., Matsumaru, D., Ryoke, R., Saito, R., Kadoguchi, S., Saigusa, D., Saito, T., Saido, T. C., Kawashima, R., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00467-19 · Cited by 166
Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression
Andronie-Cioara, F. L., Ardelean, A. I., Nistor-Cseppento, C. D., Jurcau, A., Jurcau, M. C., Pascalau, N., & Marcu, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031869 · Cited by 164
Brain cell type-specific cholesterol metabolism and implications for learning and memory
Li, D., Zhang, J., & Liu, Q. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.01.002 · Cited by 163
Garcia-Reitboeck, P., Phillips, A., Piers, T. M., Villegas-Llerena, C., Butler, M., Mallach, A., Rodrigues, C., Arber, C. E., Heslegrave, A., Zetterberg, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.094 · Cited by 162
CD33 modulates TREM2: convergence of Alzheimer loci
Chan, G., White, C. C., Winn, P. A., Cimpean, M., Replogle, J. M., Glick, L. R., Cuerdon, N. E., Ryan, K. J., Johnson, K. A., Schneider, J. A., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4126 · Cited by 162
TREM2 inhibits inflammatory responses in mouse microglia by suppressing the PI3K/NF‐κB signaling
Li, C., Zhao, B., Lin, C., Gong, Z., & An, X. (2019) · Cell Biology International · doi:10.1002/cbin.10975 · Cited by 162
“…with the ligands exposed in microglia, the immunoreceptor tyrosinebased activation motif-based transduction complex is phosphorylated, which in turn activates the downstream signaling and finally leads to cellular response (Luo et al., 2014; Jay et al., 2015; Wang et al., 2016; Choi et al., 2017).”
BackgroundGenetics ignite focus on microglial inflammation in Alzheimer’s disease
Malik, M., Parikh, I., Vasquez, J. B., Smith, C., Tai, L., Bu, G., LaDu, M. J., Fardo, D. W., Rebeck, G. W., & Estus, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0048-1 · Cited by 161
“We hypothesize that enhanced TREM2 function reduces AD risk, although as discussed above, this hypothesis is not supported by all current data [29, 57, 58].”
BackgroundResultInfluentialPeripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity
Liu, Q., Johnson, E. M., Lam, R. K., Wang, Q., Bo Ye, H., Wilson, E. N., Minhas, P. S., Liu, L., Swarovski, M. S., Tran, S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0421-2 · Cited by 159
Toward more predictive genetic mouse models of Alzheimer’s disease
Onos, K. D., Sukoff Rizzo, S. J., Howell, G. R., & Sasner, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.12.003 · Cited by 156
Alzheimer’s Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia
Eshraghi, M., Adlimoghaddam, A., Mahmoodzadeh, A., Sharifzad, F., Yasavoli-Sharahi, H., Lorzadeh, S., Albensi, B. C., & Ghavami, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073330 · Cited by 158
High‐affinity interactions and signal transduction between Aβ oligomers and TREM 2
Lessard, C. B., Malnik, S. L., Zhou, Y., Ladd, T. B., Cruz, P. E., Ran, Y., Mahan, T. E., Chakrabaty, P., Holtzman, D. M., Ulrich, J. D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809027 · Cited by 154
“…et al, 2016; Jay et al, 2017) and (ii) the lack of homing of microglial to plaques that is observed in knockout mouse models (Ulrich et al, 2014; Jay et al, 2015, 2017; Wang et al, 2015, 2016; Yuan et al, 2016), it is intriguing to consider that high-affinity interaction 6 of 13 EMBO Molecular…”
BackgroundTREM2 Function in Alzheimer’s Disease and Neurodegeneration
Ulrich, J. D., & Holtzman, D. M. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00313 · Cited by 154
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Arginase 1+ microglia reduce Aβ plaque deposition during IL-1β-dependent neuroinflammation
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0411-8 · Cited by 152
“However, some have argued that loss of TREM2 results in amelioration of Aβ pathology [42].”
BackgroundThe Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
Single-Cell RNA Sequencing: Unraveling the Brain One Cell at a Time
Ofengeim, D., Giagtzoglou, N., Huh, D., Zou, C., & Yuan, J. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.04.006 · Cited by 149
“These studies are particularly relevant because an emerging concept in the field of neurodegeneration includes the role of immune dysfunction in driving disease pathology [73] [74].”
BackgroundBhattacharjee, S., Zhao, Y., Dua, P., Rogaev, E. I., & Lukiw, W. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150211 · Cited by 147
Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets
Nizami, S., Hall‐Roberts, H., Warrier, S., Cowley, S. A., & Di Daniel, E. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14618 · Cited by 147
“However, the effects on amyloid plaque number in these models vary, depending on the genetic background, age, and brain region examined (Jay, Hirsch, et al., 2017; Jay et al., 2015; Krasemann et al., 2017; Wang et al., 2015; Wang et al., 2016).”
BackgroundPrice, B. R., Sudduth, T. L., Weekman, E. M., Johnson, S., Hawthorne, D., Woolums, A., & Wilcock, D. M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01915-0 · Cited by 146
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 153
Human iPSC‐derived microglia: A growing toolset to study the brain's innate immune cells
Hasselmann, J., & Blurton‐Jones, M. (2020) · Glia · doi:10.1002/glia.23781 · Cited by 145
“…TREM2 gene variants with AD risk (Guerreiro, Wojtas, et al., 2013; Jonsson et al., 2013), the resulting decreases in migration and barrier formation in response to Aβ plaques were first identified in multiple mouse models of AD (Jay et al., 2015; Ulrich et al., 2014; Y. Wang et al., 2015).”
BackgroundTherapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 153
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Henjum, K., Almdahl, I. S., Årskog, V., Minthon, L., Hansson, O., Fladby, T., & Nilsson, L. N. G. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0182-1 · Cited by 143
“However, the effects of TREM2 deficiency on amyloid plaque load in AβPP transgenic mice are inconsistent [41–43].”
BackgroundZhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141
“TREM2 deficiency considerably reduced microglia clustering around plaques, microglial survival, and microgliosis in 5XFAD and APPPS1 mouse models of AD (13, 15).”
BackgroundEwers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012308 · Cited by 133
“…is consistent with the proposal that any TREM2-dependent beneficial effects on amyloid are stage-dependent and occur preferentially at later stages of Ab (Jay et al, 2017), which may explain why some studies did not find a beneficial effect of TREM2 on Ab (Jay et al, 2015; Krasemann et al, 2017).”
Protective Microglial Subset in Development, Aging, and Disease: Lessons From Transcriptomic Studies
Benmamar-Badel, A., Owens, T., & Wlodarczyk, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00430 · Cited by 124
“Nonetheless, all these studies demonstrate lack of microglial proliferation and clustering around plaques in TREM2-deficient animals, thus allowing for more dispersed Aβ localization in AD models (75, (112) (113) (114) (115) (116) .”
BackgroundKorvatska, O., Leverenz, J. B., Jayadev, S., McMillan, P., Kurtz, I., Guo, X., Rumbaugh, M., Matsushita, M., Girirajan, S., Dorschner, M. O., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0979 · Cited by 137
Self-citationAlzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy
Clayton, K. A., Van Enoo, A. A., & Ikezu, T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00680 · Cited by 134
“…with some stipulating that TREM2 in microglia increase phagocytosis and clearance of Aβ (Wang et al., 2015; Xiang et al., 2016; Yuan et al., 2016), while others have suggested that disruption of TREM2 reduces amyloid plaque load (Ulrich et al., 2014; Jay et al., 2015; Krasemann et al., 2017).”
BackgroundMicroglia in Alzheimer’s disease: A multifaceted relationship
ElAli, A., & Rivest, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.021 · Cited by 134
“Importantly, TREM2 depletion eliminated CD45high macrophages, which significantly reduced inflammation and ameliorated AD-like pathology in transgenic mice, thus suggesting a detrimental role of TREM2-positive macrophages in AD pathology (Jay et al., 2015).”
BackgroundInfluentialMicroglial Malfunction: The Third Rail in the Development of Alzheimer's Disease
Mhatre, S. D., Tsai, C. A., Rubin, A. J., James, M. L., & Andreasson, K. I. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.006 · Cited by 134
“In another study, TREM2-deficient APP/PS1 mice similarly showed reduced numbers of myeloid cells around amyloid plaques, and TREM2 expression was found to be specifically associated with CD11b/CD45 macrophages, suggesting that TREM2 functions in peripheral infiltrating macrophages [18].”
N -glycan and Alzheimer's disease
Kizuka, Y., Kitazume, S., & Taniguchi, N. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.04.012 · Cited by 141
Long, H., Simmons, A., Mayorga, A., Burgess, B., Nguyen, T., Budda, B., Rychkova, A., Rhinn, H., Tassi, I., Ward, M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01599-1 · Cited by 124
“TREM2 knockout has been reported to produce variable effects on Aβ load depending on the mouse model and disease stage [15, 24, 26, 27] but consistently results in increased neuritic dystrophy [23, 27, 28].”
BackgroundMicroglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
“However, there is conflicting data on 148 whether Trem2 knockout increases or decreases overall plaque burden(58–60), even 149 though TREM2-/- microglia have reduced phagocytic capacity in culture(56, 61).”
InfluentialShi, Q., Chang, C., Saliba, A., & Bhat, M. A. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.2427-21.2022 · Cited by 127
Cheng, Q., Danao, J., Talreja, S., Wen, P., Yin, J., Sun, N., Li, C.-M., Chui, D., Tran, D., Koirala, S., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001848 · Cited by 129
Walker, D. G., Tang, T. M., Mendsaikhan, A., Tooyama, I., Serrano, G. E., Sue, L. I., Beach, T. G., & Lue, L.-F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020678 · Cited by 128
“Recent findings have defined a phenotype of microglia designated “disease-associated microglia” (DAM), which describes a transcriptional signature first associated with response to neurodegeneration-associated molecular patterns (DAM stage 1) that progresses to a signature associated with a protective role to limit in…”
BackgroundPiirainen, S., Youssef, A. M., Song, C., Kalueff, A. V., Landreth, G. E., Malm, T., & Tian, L. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.046 · Cited by 136
Self-citationHaure-Mirande, J.-V., Audrain, M., Fanutza, T., Kim, S. H., Klein, W. L., Glabe, C., Readhead, B., Dudley, J. T., Blitzer, R. D., Wang, M., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1737-3 · Cited by 127
“Thus, the effect of a decreased Tyrobp expression on the stoichiometry of TAU phosphorylation appeared to be different in the presence or absence of APP/PSEN1 mutations leading to amyloid deposition.”
BackgroundInfluentialRangaraju, S., Raza, S. A., Li, N. X., Betarbet, R., Dammer, E. B., Duong, D., Lah, J. J., Seyfried, N. T., & Levey, A. I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00405 · Cited by 126
“who also found that 5xFAD CD45high CNS MPs selectively upregulated TREM2 expression in an age-dependent manner (69).”
BackgroundTargeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Self-citationTREM2: Potential therapeutic targeting of microglia for Alzheimer's disease
Li, Y., Xu, H., Wang, H., Yang, K., Luan, J., & Wang, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115218 · Cited by 126
Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., et al. (2018) · Brain · doi:10.1093/brain/awx346 · Cited by 125
“…immune cells into the brain in Alzheimer’s dis- ease mouse models or in human Alzheimer’s disease brains (Bien-Ly et al., 2015; Prinz and Priller, 2017), many brain mononuclear phagocytes that surround amyloid-b plaques are CD45high, suggesting their peripheral monocyte origin (Jay et al., 2015).”
BackgroundTeter, B., Morihara, T., Lim, G. P., Chu, T., Jones, M. R., Zuo, X., Paul, R. M., Frautschy, S. A., & Cole, G. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.015 · Cited by 124
“, 2010), which may occur in invading macrophages (Jay et al., 2015) or resident microglia (Hickman and El Khoury, 2014; Wang et al.”
BackgroundDifferential contribution of microglia and monocytes in neurodegenerative diseases
Baufeld, C., O’Loughlin, E., Calcagno, N., Madore, C., & Butovsky, O. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1795-7 · Cited by 123
“On one hand, they demonstrate that the homeostatic microglia marker P2Y12 is lost in active MS lesions, but reappears in inactive lesions.”
BackgroundInfluentialSelf-citationThe Early Events That Initiate β-Amyloid Aggregation in Alzheimer’s Disease
Zhang, X., Fu, Z., Meng, L., He, M., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00359 · Cited by 122
“However, a TREM2 deficiency in APP/PS1 mice led to a dramatic reduction in Aβ plaque burden (Jay et al., 2015).”
BackgroundInflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 121
“However, while knockout of TREM2 robustly impairs microglial clustering around amyloid plaques in mice, it has produced inconsistent results on amyloid plaque load (Jay et al. 2015; Wang et al. 2015), which may be because of different roles of TREM2 in different stages of disease (Jay et al. 2017).”
BackgroundResultTREM2 regulates microglial lipid droplet formation and represses post-ischemic brain injury
Wei, W., Zhang, L., Xin, W., Pan, Y., Tatenhorst, L., Hao, Z., Gerner, S. T., Huber, S., Juenemann, M., Butz, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115962 · Cited by 122
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 126
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 119
Prokop, S., Miller, K. R., Labra, S. R., Pitkin, R. M., Hoxha, K., Narasimhan, S., Changolkar, L., Rosenbloom, A., Lee, V. M.-Y., & Trojanowski, J. Q. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02048-2 · Cited by 119
Inhomogeneous distribution of Iba‐1 characterizes microglial pathology in Alzheimer's disease
Tischer, J., Krueger, M., Mueller, W., Staszewski, O., Prinz, M., Streit, W. J., & Bechmann, I. (2016) · Glia · doi:10.1002/glia.23024 · Cited by 118
“In fact, further contradictory data exists regarding the role of microglia in the elimination of amyloid (Jay et al., 2015; Mildner et al., 2011), for example, the fact that TREM2 promotes phagocytosis and transcription of anti-inflammatory cytokines and suppresses production of proinflammatory cytokines (Takahashi et…”
BackgroundJiang, T., Tan, L., Zhu, X.-C., Zhou, J.-S., Cao, L., Tan, M.-S., Wang, H.-F., Chen, Q., Zhang, Y.-D., & Yu, J.-T. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.019 · Cited by 111
Wang, H., Robinson, J. L., Kocabas, P., Gustafsson, J., Anton, M., Cholley, P.-E., Huang, S., Gobom, J., Svensson, T., Uhlen, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102344118 · Cited by 117
“Notably, the gene sets of reporter metabolites (GM2A, H+, Pi, H 2 O, ADP, and ATP) associated with lysosome (Dataset S3) were uniformly enriched in the APP overexpression models after A β deposition but absent from the hybrid Trem2 KO (KOMP) × APPPS1 model (Fig.”
InfluentialImpact of peripheral myeloid cells on amyloid-β pathology in Alzheimer’s disease–like mice
Prokop, S., Miller, K. R., Drost, N., Handrick, S., Mathur, V., Luo, J., Wegner, A., Wyss-Coray, T., & Heppner, F. L. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150479 · Cited by 116
“…remained unchanged upon peripheral macrophage infiltration, suggesting that both resident microglia and peripheral myeloid cells can contribute to TREM2 protein expression in the brain, an issue which has been discussed controversially (Frank et al., 2008; Ulrich et al., 2014; Jay et al., 2015).”
BackgroundAminophospholipids are signal-transducing TREM2 ligands on apoptotic cells
Shirotani, K., Hori, Y., Yoshizaki, R., Higuchi, E., Colonna, M., Saito, T., Hashimoto, S., Saito, T., Saido, T. C., & Iwata, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-43535-6 · Cited by 116
Microbiota modulation as preventative and therapeutic approach in Alzheimer’s disease
Bonfili, L., Cecarini, V., Gogoi, O., Gong, C., Cuccioloni, M., Angeletti, M., Rossi, G., & Eleuteri, A. M. (2021) · The FEBS Journal · doi:10.1111/febs.15571 · Cited by 115
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Gratuze, M., Schlachetzki, J. C. M., D’Oliveira Albanus, R., Jain, N., Novotny, B., Brase, L., Rodriguez, L., Mansel, C., Kipnis, M., O’Brien, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.022 · Cited by 115
Lau, S.-F., Chen, C., Fu, W.-Y., Qu, J. Y., Cheung, T. H., Fu, A. K. Y., & Ip, N. Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107530 · Cited by 114
“Specifically, the induction of DAMs at the early stage of AD is beneficial to Ab pathology but becomes detrimental upon disease progression (Deczkowska et al., 2018; Jay et al., 2015; Parhizkar et al., 2019).”
BackgroundInfection, systemic inflammation, and Alzheimer's disease
Lim, S., Rodríguez‐Ortiz, C. J., & Kitazawa, M. (2015) · Microbes and Infection · doi:10.1016/j.micinf.2015.04.004 · Cited by 128
Graham, L. C., Harder, J. M., Soto, I., de Vries, W. N., John, S. W. M., & Howell, G. R. (2016) · Scientific Reports · doi:10.1038/srep21568 · Cited by 112
Self-citationElevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, N., Qiao, W., Li, F., Ren, Y., Zheng, J., Martens, Y. A., Wang, X., Li, L., Liu, C.-C., Chen, K., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20212479 · Cited by 111
“Unfortunately, the effects of Trem2 deficiency on amyloid load have yielded inconsistent results (Jay et al., 2017; Jay et al., 2015; Parhizkar et al., 2019; Ulrich et al., 2017; Wang et al., 2015; Wang et al., 2016).”
ResultA cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer’s disease
Yoo, Y., Neumayer, G., Shibuya, Y., Mader, M. M.-D., & Wernig, M. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.07.006 · Cited by 109
Central nervous system myeloid cells as drug targets: current status and translational challenges
Biber, K. P. H., Möller, T., Boddeke, E., & Prinz, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.14 · Cited by 116
Neuroprotective Effect of TREM-2 in Aging and Alzheimer’s Disease Model
Raha, A. A., Henderson, J. W., Stott, S. R. W., Vuono, R., Foscarin, S., Friedland, R. P., Zaman, S. H., & Raha-Chowdhury, R. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160663 · Cited by 111
Fassler, M., Rappaport, M. S., Cuño, C. B., & George, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01980-5 · Cited by 110
“results, demonstrating either an anti-inflammatory or a pro-inflammatory role for TREM2 [4, 6, 7, 15, 18].”
ResultZheng, H., Liu, C.-C., Atagi, Y., Chen, X.-F., Jia, L., Yang, L., He, W., Zhang, X., Kang, S. S., Rosenberry, T. L., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.004 · Cited by 110
A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese
Jiang, T., Tan, L., Chen, Q., Tan, M.-S., Zhou, J.-S., Zhu, X.-C., Lu, H., Wang, H.-F., Zhang, Y.-D., & Yu, J.-T. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.023 · Cited by 110
“Under AD condition, TREM2 was revealed to exert a protective effect by enhancement of Ab clearance and suppression of inflammatory response (Wang et al., 2015), although the opposite result was reported by Jay et al. (2015).”
Result
Metadata
- Authors
- Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., & Lamb, B. T.
- Affiliations
- Cleveland Clinic (US)
- The Lerner Research Institute 1 and 2
- Jackson Laboratory (US)
- Case Western Reserve University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Lamb, Bruce T.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-03-02
- Volume
- 212
- Issue
- 3
- Pages
- 287-295
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4354365
- OpenAlex
- W2155344647
- Cited by
- 682
- References
- 33
- Citations by year
- 2026: 27 · 2025: 56 · 2024: 46 · 2023: 56 · 2022: 74 · 2021: 62 · 2020: 70 · 2019: 59 · 2018: 65 · 2017: 67 · 2016: 54 · 2015: 45
- FWCI
- 41.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000439)
- National Institute on Aging (R01AG023012, AG023012, F31AG048704)
- National Institute of General Medical Sciences (T32GM007250)
- National Institute of Neurological Disorders and Stroke (NS047804, T32NS067431, NS087298, R01NS088137, T32NS077888)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- TREM2, Alzheimer's disease, inflammatory macrophages, microglia, amyloid deposits, tau pathology, neuroinflammation, amyloidosis
- MeSH terms
- Age Factors, Aged, Alzheimer Disease, Animals, Disease Models, Animal, Female, Hippocampus, Humans, Macrophages, Male, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Up-Regulation, Amyloid beta-Peptides, tau Proteins, Leukocyte Common Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.